Please check your internet connection and try again.
# Sompraz HP
## Overview
Sompraz HP is a combination product containing pantoprazole, amoxicillin, and clarithromycin. Pantoprazole is a proton pump inhibitor (PPI) that reduces stomach acid production. Amoxicillin and clarithromycin are antibiotics used to eradicate *Helicobacter pylori* (*H. pylori*).
## Primary Indications
Treatment of *H. pylori* infection in patients with peptic ulcer disease.
## Adult Dosing
The standard adult dose is one dose pack taken twice daily for 7 days. Each dose pack contains:
* Pantoprazole 40 mg delayed-release tablet
* Amoxicillin 500 mg capsule
* Clarithromycin 500 mg tablet
Patients should take all medications in the dose pack at the same time, twice daily, for the full 7-day course.
## Pediatric Dosing
Dosing for pediatric patients is not established for Sompraz HP. Individual components may have pediatric dosing, but this combination product is not recommended for use in children.
## Dose Adjustments
No dose adjustments are typically required for patients with renal or hepatic impairment for the combination product as prescribed for 7 days. However, caution may be warranted in severe hepatic impairment with prolonged use of pantoprazole.
## Contraindications
* Known hypersensitivity to pantoprazole, amoxicillin, clarithromycin, or any component of the formulation.
* History of allergic reactions to penicillins, cephalosporins, or other beta-lactam antibiotics.
* History of cholestatic jaundice or hepatic dysfunction associated with prior clarithromycin use.
* Use in patients with rare hereditary problems of galactose intolerance, severe lactase deficiency or glucose-galactose malabsorption (due to lactose content in amoxicillin capsules).
* Use in patients with active *H. pylori* infection and a history of macrolide resistance.
## Adverse Effects
Common adverse effects include diarrhea, nausea, headache, abdominal pain, vomiting, rash, and dysgeusia (altered taste). Serious adverse effects include severe allergic reactions, *Clostridioides difficile*-associated diarrhea, QT prolongation (clarithromycin), and hepatic dysfunction.
## Key Drug Interactions
* **Warfarin:** Increased INR and bruising (monitor INR closely).
* **Methotrexate:** Increased methotrexate levels, potentially leading to toxicity (monitor for methotrexate toxicity).
* **Ketoconazole, Itraconazole:** Reduced absorption of these antifungals due to pantoprazole's acid suppression.
* **CYP3A4 Substrates (e.g., simvastatin, lovastatin, cyclosporine, tacrolimus, rifabutin):** Clarithromycin is a moderate inhibitor of CYP3A4, potentially increasing levels of these drugs.
* **Theophylline:** Clarithromycin may increase theophylline levels.
* **Digoxin:** Clarithromycin may increase digoxin levels.
* **Proton Pump Inhibitors:** Additive effect on gastric pH reduction.
## Monitoring
* Monitor for signs and symptoms of allergic reactions.
* Monitor for diarrhea, especially *C. difficile*-associated diarrhea.
* Monitor INR if the patient is on warfarin.
* Monitor for signs of methotrexate toxicity if co-administered.
* Follow up to confirm *H. pylori* eradication is typically recommended (e.g., via stool antigen test or urea breath test) 4-6 weeks after completing therapy.
## Clinical Pearls
* This is a 7-day regimen. Ensure patients understand the full duration of therapy.
* Administer the dose pack at the same time twice daily.
* Inform patients about potential adverse effects, particularly diarrhea and altered taste.
* Advise patients to complete the full course of antibiotics even if they feel better.
* Consider potential for antibiotic resistance when prescribing.
***
**Disclaimer:** This information is intended for clinical use and does not replace professional medical judgment. Always consult the most current prescribing information and local institutional guidelines before making clinical decisions.
